Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista Colombiana de Cardiología
versión impresa ISSN 0120-5633
Resumen
GUZMAN, Guillermo; GOMEZ, Juan Esteban; PLAZA, Leidy Johanna y SANCHEZ, María Claudia. Oral glucose-lowering drugs and cardiovascular risk. Rev. Colomb. Cardiol. [online]. 2018, vol.25, n.5, pp.333-339. ISSN 0120-5633. https://doi.org/10.1016/j.rccar.2017.10.009.
Introduction:
Cardiovascular disease is the main cause of death worldwide, as well as the first cause of morbidity and mortality in patients with diabetes mellitus. For these reasons it is important to know the different drugs currently available to manage diabetes mellitus and their positive and negative effects at cardiovascular level. Hence, different scientific societies and associations of the world have issued the recommendation that all drugs for the treatment of type 2 diabetes mellitus must be evaluated and certified as safe at cardiovascular level.
Methodology:
An extensive search was carried out on the existing literature on current antidiabetic drugs and their cardiovascular effects.
Results:
There are different types of drugs that are associated with a decrease or increase in cardiovascular risk. Currently, there is evidence that associated metformin (biguanide), empagliflozin (sodium-glucose cotransporter 2 inhibitor), and liraglutide (a glucagon-like peptide analogue), with less cardiovascular deaths and cardiovascular events in patients with established cardiovascular disease.
Conclusion:
Patients with known cardiovascular disease may have an additional benefit in selecting glucose-lowering drugs with a better cardiovascular safety profile.
Palabras clave : Cardiovascular risk; Antidiabetics; Empagliflozin; Liraglutide.